MA-ANTERRA-CAPITAL
29.6.2021 14:02:13 CEST | Business Wire | Press release
Anterra Capital (“Anterra”), the international food and agriculture specialist venture capital firm, today announced the initial closing of its second food and agriculture technology fund, Anterra F&A Ventures II, raising $175 million, exceeding the targeted size of the fund. Due to the positive market reception for the fund’s mission and strategy, Anterra is tracking towards an upsized second fund, and anticipates a final closing in the third quarter, 2021.
Anterra’s unique investment approach has attracted commitments from a prestigious and aligned group of long-term oriented global investors, with continued support from Eight Roads Ventures, backed by Fidelity, and Rabo Investments, the captive investment arm of the largest global food and agricultural bank out of the Netherlands - Rabobank. New investors include Novo Holdings, a leading global life sciences investor based out of Denmark; Tattarang, one of Australia’s largest private investment groups and the holding company of the Forrest family’s private business interests; as well as other well-respected family offices, sovereign wealth funds, and state-owned investors that provide a global presence, spanning across multiple continents.
Anterra’s mission is to invest in and partner with entrepreneurs transforming our vital food economy through biotech and digital innovation across crop science, animal health, and human nutrition. As a research driven, value-focused specialist investor Anterra uniquely combines a traditional venture investment approach and “venture creation,” building and scaling transformative businesses with its deep industry knowledge and vast global network as a pioneer in the space. While investor interest is growing in the Food & Ag industry, early-stage investment in this essential segment significantly trails that of other key industries, for comparison, less than half of that in Pharma & Biotech (~$40 billion) and about a fifth of venture investment in Software (~$100 billion).
“The food economy is in critical condition, and new digital and biotech solutions are desperately needed in order to support better outcomes for farmers, consumers and the environment,” said Adam Anders, Managing Partner of Anterra Capital. “With the first close, we continue our mission to sustainably transform our food economy, building on our leadership position as an early-stage investor in markets such as plant and animal health, while actively expanding our investment activity across the food and agriculture value chain.”
Daniel Auerbach, Senior Managing Partner and Global Head of Eight Roads Ventures, one of Anterra’s original lead investors, added: “Within Food & Ag, Anterra sits at the intersection of life sciences and digital technology and our expanded investment reflects our confidence in Anterra’s mission, leadership and performance for us over the past eight years.”
“We are excited to partner with Anterra and support the fund’s transformational mission, which is aligned with our investment activity across the biotech space overall, and emphasizes our commitment to investing in innovation within Food & Agriculture,” said Kartik Dharmadhikari, a Partner of Novo Growth within Novo Holdings.
About Anterra
With offices in Amsterdam and Boston, Anterra Capital is an international specialist venture capital investor dedicated to financing the growth of technology-driven companies with incredible potential in food, agriculture, and animal health. Supported by multinational institutional investors, Anterra provides patient strategic capital to entrepreneurs and innovative companies sustainably transforming our global food system. Further information: www.anterracapital.com
About Eight Roads Ventures
Eight Roads Ventures is a global investment firm backed by Fidelity. Eight Roads Ventures manages $7bn of assets across its offices in China, Hong Kong, India, Japan, UK and the US. Our 50-year history of investing includes partnerships with over 300 companies such as Alibaba, AppsFlyer, BlackDuck, Chewy, Devoted Health, Flywire, Icertis, iPipeline, Kensho, Letgo, Made.com, Neo4j, Nuance, Paidy, Ping Identity, Pony.ai, PharmEasy, Shadowfax, Toast, Wallapop, WuXi PharmaTech, and Xoom. Further information: https://eightroads.com
About Novo Holdings A/S
Novo Holdings is recognized as a leading international life science investor, with a focus on creating long-term value. As a life science investor, Novo Holdings provides seed and venture capital to development-stage companies and takes significant ownership positions in growth and well-established companies. Novo Holdings also manages a broad portfolio of diversified financial assets. Further information: http://www.novoholdings.dk
About Rabo Investments
Rabo Investments is Rabobank’s PE investment franchise. It has invested over €1.5 billion worldwide within the cutting-edge Food & Agri, Sustainability, and Healthcare sectors in the Netherlands and within the Food & Agri sector worldwide. The investments range from growth capital for innovative start-ups and scale-ups to investments in established companies and funds. Further information: https://raboinvestments.com
About Tattarang
Tattarang is one of Australia’s largest private investment groups and is owned by the Forrest family. Its diverse investment portfolio spans across agri-food, energy, resources, property and lifestyle. The group is made up of six business divisions including Harvest Road which is one of Australia’s largest and most diverse agricultural businesses with an expanding portfolio of high-quality foods. Further information: www.tattarang.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210629005357/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Westlake Expands Global Chlorovinyls Manufacturing Capacity With Acquisition of PVC and VCM Plants in Wilhelmshaven, Germany15.6.2026 20:18:00 CEST | Press release
Westlake Corporation (NYSE: WLK) (“Westlake”) announced today that its German subsidiary, Westlake Vinnolit GmbH & Co. KG, has completed the previously-announced acquisition of a polyvinyl chloride and vinyl chloride monomer production site located in Wilhelmshaven, Germany (the “Wilhelmshaven plant”). The Wilhelmshaven plant, which was previously in insolvency administration, has the capacity to produce 380,000 metric tons of PVC per year. “This acquisition strengthens our Performance & Essential Materials business by expanding our global chlorovinyls manufacturing footprint and complements our existing chlorovinyl production facilities in Europe and North America,” said Jean-Marc Gilson, President and Chief Executive Officer of Westlake. “The Wilhelmshaven plant, which is located in Lower Saxony on Germany’s North Sea coast, benefits from advantageous logistical infrastructure, including a deep-water dock that enables efficient raw-materials supply. We look forward to welcoming the s
Onera Announces Integration of the Onera hPSG® Solution With Somnoware15.6.2026 19:35:00 CEST | Press release
Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire workflow in Somnoware. Onera Health, a leader in transforming sleep medicine, announces that its end-to-end home polysomnography solution, the Onera hPSG® solution, now integrates with Somnoware by ResMed sleep lab management software. This integration enables clinicians to conduct Polysomnography tests (PSGs) where patients sleep most comfortably, in their own home, while managing the entire workflow in Somnoware. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615106079/en/ Onera hPSG®, an end-to-end home polysomnography solution from Onera Health, is now integrated into Somnoware, enabling their shared customers to conduct Polysomnography tests (PSGs) in the patient's home while managing the entire wo
Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation15.6.2026 18:18:00 CEST | Press release
A global platform mobilizing expertise and collective action to advance shared digital priorities The Digital Cooperation Organization (DCO), the world's first standalone international organization dedicated to inclusive and sustainable digital economy growth, today announced the launch of the Global Expert Community (GEC) — a new platform designed to mobilize expertise and advance international collaboration in support of high-impact digital initiatives across DCO Member States and beyond. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615565781/en/ Digital Cooperation Organization Launches Global Expert Community to Accelerate International Digital Cooperation (Graphic: AETOSWire) The GEC reflects the DCO's continued commitment to turning digital cooperation into action by expanding access to specialized expertise and strengthening collaboration across sectors and borders. As digital transformation reshapes economies an
New Pivotal Study Data Show Takeda’s Oveporexton Improved Daily Function, Cognition and Nighttime Sleep for People with Narcolepsy Type 115.6.2026 18:00:00 CEST | Press release
- Secondary and Exploratory Endpoint Results from Phase 3 Studies Presented at SLEEP 2026 Underscore Improvements with Oveporexton Across a Broad Range of Daytime and Nighttime Symptoms - Takeda is on Track to Bring the First and Only Orexin Agonist to People Living with Narcolepsy Type 1 with Regulatory Submissions Under Review Takeda (TSE:4502/NYSE:TAK)today presented additional results from two pivotal studies at SLEEP 2026, showing oveporexton (TAK-861), an oral orexin receptor 2 (OX2R)-selective agonist, improved daily functioning as well as cognitive and sleep-related symptoms associated with narcolepsy type 1 (NT1).1,2,3 Oveporexton is designed to address the underlying orexin deficiency that causes NT1 by restoring orexin signaling. These data, along with previously disclosed Phase 3 results, demonstrated improvement across the broad disease spectrum, supporting the potential of oveporexton to redefine the standard of care for NT1.4 "Narcolepsy type 1 is a 24-hour disease drive
Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders15.6.2026 17:30:00 CEST | Press release
For Boomi, this recognition reinforces its vision and momentum in enterprise agentic AI Boomi, the data activation company for AI, today announced it has been recognized as aPioneer in the Gartner® Emerging Market Quadrant for No-Code Agent Builders (NCAB). Gartner defines the NCABs market as SaaS-delivered products that offer an integrated design and runtime environment to build, publish and manage AI-powered agents without using coding. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260615413216/en/ Boomi Named a Pioneer in June 2026 Gartner® Emerging Market Quadrant for No-Code Agent Builders Boomi sees this recognition as a reflection of the company's rapid evolution from an integration and automation powerhouse to a full-scale agentic infrastructure platform, expanding Boomi’s role in the emerging agentic AI market. A New Chapter in Enterprise Agentic AI According to Gartner, vendors recognized as a Pioneer in this quad
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom